GXO Logistics Inc vs Vaxcyte Inc. Common Stock — how do they compare? GXO Logistics Inc trades at $45.88 (market cap $5.33B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 29 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GXO | PCVX | |
|---|---|---|
Market Cap | $5.33B | $10.51B |
Volume | 961,023 | 2,644,694 |
Sector | Industrials | Health |
52-Week High | $65.59 | $73.82 |
52-Week Low | $44.17 | $40.32 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $10.68B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.50, down 0.21% with neutral technical signals. The company shows strong revenue growth with 2026 revenue reaching $13.6B and net profit margin improving to 0.96%. Recent earnings beats and strategic partnerships in Europe and aerospace sectors demonstrate operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and a $66.67 price target, representing 43% upside potential from current levels.
The stock presents compelling value with attractive valuation metrics including P/S of 0.39x, though elevated P/E of 41.15x reflects growth expectations. Key risks include margin pressure from new business at lower incremental margins and competitive industry dynamics. The improving freight industry outlook and GXO's market leadership position support long-term growth prospects despite near-term execution challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →